Business
Vortex Improves CTC Enumeration with Impedance
Vortex Improves CTC Enumeration with Impedance.
About this update from Emv Capital Plc
[{"type":"text","content":"\n \nRNS Number : 6969G NetScientific PLC 08 November 2018 \n\n \n \n \n \nNetScientific plc\n(\"NetScientific\" or the \"Company\" or the \"Group\")\n \n \nVortex Biosciences paves the way forward in CTC enumeration by introducing impedance measurements\n \nLondon, UK - 08 November 2018 - NetScientific plc (\"NetScientific\", AIM:NSCI), the transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, has presented a study that demonstrates the feasibility of combining its technology with impedance spectroscopy to improve the analysis of circulating tumour cells (CTCs). \n \nThe study presented at NanoBiotech Montreux 2018 introduces the coupling of Vortex technology with an impedance chip for counting and sizing of cancer cells isolated from blood samples. The researchers believe the results provide feasibility for label-free, reliable, fully-integrated cell enumeration, whilst keeping the cells collected intact for downstream transcriptomic, genomic or proteomic analysis.\n\"With this collaboration and the resulting proof of concept we can apply impedance spectroscopy to the analysis of rare cancer cells. This is a first step towards the use of CTCs for clinical practice\" said Pr. Renaud of the Ecole Polytechnique Federale de Lausanne (EPFL).\n \nCommenting on the news, Francois Martelet, Chairman of Vortex BioSciences Inc. and CEO of NetScientific said: \"These improvements in sizing and enumeration position Vortex at the very forefront of CTC analysis. By creating a fully automated and reliable process and recently having reached an agreement with STRATEC for mass-manufacturing, Vortex's technology is ready to be adopted by large pharmaceutical players to improve how oncology treatment is determined.\"\n \n \nNetScientific holds 66.1% of Vortex Biosciences on a fully diluted basis.\n \n# # #\n \nFor more information, please contact:\n \n\n\n\n NetScientific\n François R. Martelet, M.D., CEO\n Ian Postlethwaite, CFO\n\n\nTel: +44 (0)20 3514 1800\n\n\n\n\n \n Consilium Strategic Communications\n Mary-Jane Elliott / Chris Welsh / \n Laura Thornton \n\n\n \nTel: +44 (0)20 3709 5700\[email protected]\n\n\n\n\nW...